Latest Breaking News On - ரோஜர் ச ou - Page 1 : comparemela.com
COVID-19 News from Annals of Internal Medicine
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
The Evolving Science of Face Masks and COVID-19
factcheck.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from factcheck.org Daily Mail and Mail on Sunday newspapers.
Racial minorities more likely to become infected with COVID-19
An analysis of Kaiser Permanente members in Northern California early in the COVID-19 pandemic found that racial minorities were more likely than white patients to test positive for COVID-19. The findings are published in
Annals of Internal Medicine.
Researchers from Kaiser Permanente, The Permanente Medical Group, and Stanford Cancer Institute studied health records for 3.5 million patients in the Kaiser Health system, more than 91,000 of whom received a COVID-19 test between Feb. 1 and May 31, 2020. That data showed that Latino patients were nearly 4 times as likely as white patients to become infected with the virus, while Asian and Black patients were 2 times as likely to test positive for COVID-19 compared to white patients. The odds of hospitalization were also higher for Latino, Asian, and Black patients with COVID-19 than for white patients. However, the study did not find racial disparities in mortality amon
Face Masks Protect Wearers, Others From COVID: Studies
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
The New England Journal of Medicine.
No cases of severe COVID-19 occurred among participants who received the vaccine, known as mRNA-1273, and there were no safety concerns.
The US Food and Drug Administration on December 18 issued an emergency use authorization for the vaccine, a lipid-nanoparticle-encapsulated mRNA vaccine expressing the prefusion-stabilized spike glycoprotein.
The trial began in July and enrolled 30,420 adults in the United States. Volunteers were randomly assigned in a 1:1 ratio to receive either two doses of the vaccine or two shots of saline placebo 28 days apart. The average age of the participants was 51 years.
In all, 196 cases of symptomatic COVID-19 occurred at least 14 days after participants received their second shot 185 cases in the placebo group, and 11 in the vaccine group.